Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeanine Walenga

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 17, 2011
Contaminants in heparinRussell Hull, Jeanine Walenga
International Angiology : a Journal of the International Union of Angiology|May 11, 2018
Medical management of stable peripheral artery disease: the COMPASS trial. Perspectives from a vascular standpointEduardo Ramacciotti, Valter Castelli, Jeanine Walenga, et al.
Drug Safety|June 20, 2003
Benefit-risk assessment of treatments for heparin-induced thrombocytopeniaHarry Messmore, Walter Jeske, William Wehrmacher, et al.
Seminars in Respiratory and Critical Care Medicine|February 28, 2008
The future of anticoagulationDebra A Hoppensteadt, Walter Jeske, Jeanine Walenga, et al.
Hematology/Oncology Clinics of North America|January 11, 2005
Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical useRodger L Bick, Eugene P Frenkel, Jeanine Walenga, et al.
Clinical Chemistry and Laboratory Medicine|July 14, 2015
Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international studyJob Harenberg, Shanshan Du, Martin Wehling, et al.
Clinical Pharmacokinetics|September 10, 2003
Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practiceJawed Fareed, Debra Hoppensteadt, Jeanine Walenga, et al.
Hematology/Oncology Clinics of North America|January 11, 2005
Development of generic low molecular weight heparins: a perspectiveJawed Fareed, Wendy Leong, Debra A Hoppensteadt, et al.
Research and Practice in Thrombosis and Haemostasis|June 15, 2026
Thromboinflammation and hemostatic activation drive early mortality risk in pulmonary embolismFakiha Siddiqui, Alfonso Tafur, Amir Darki, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 21, 2023
Glycemic Control and Plasma Levels of Pro-Inflammatory and Pro-Thrombotic Biomarkers in Diabetic Patients Presenting with Acute Pulmonary EmbolismAlexander O'Hara, Jacob Pozin, Amir Darki, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 17, 2011
Contaminants in heparinRussell Hull, Jeanine Walenga
International Angiology : a Journal of the International Union of Angiology|May 11, 2018
Medical management of stable peripheral artery disease: the COMPASS trial. Perspectives from a vascular standpointEduardo Ramacciotti, Valter Castelli, Jeanine Walenga, et al.
Drug Safety|June 20, 2003
Benefit-risk assessment of treatments for heparin-induced thrombocytopeniaHarry Messmore, Walter Jeske, William Wehrmacher, et al.
Seminars in Respiratory and Critical Care Medicine|February 28, 2008
The future of anticoagulationDebra A Hoppensteadt, Walter Jeske, Jeanine Walenga, et al.
Hematology/Oncology Clinics of North America|January 11, 2005
Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical useRodger L Bick, Eugene P Frenkel, Jeanine Walenga, et al.
Clinical Chemistry and Laboratory Medicine|July 14, 2015
Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international studyJob Harenberg, Shanshan Du, Martin Wehling, et al.
Clinical Pharmacokinetics|September 10, 2003
Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practiceJawed Fareed, Debra Hoppensteadt, Jeanine Walenga, et al.
Hematology/Oncology Clinics of North America|January 11, 2005
Development of generic low molecular weight heparins: a perspectiveJawed Fareed, Wendy Leong, Debra A Hoppensteadt, et al.
Research and Practice in Thrombosis and Haemostasis|June 15, 2026
Thromboinflammation and hemostatic activation drive early mortality risk in pulmonary embolismFakiha Siddiqui, Alfonso Tafur, Amir Darki, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 21, 2023
Glycemic Control and Plasma Levels of Pro-Inflammatory and Pro-Thrombotic Biomarkers in Diabetic Patients Presenting with Acute Pulmonary EmbolismAlexander O'Hara, Jacob Pozin, Amir Darki, et al.
Pageof 3